Drugs / alpha one antitrypsin
alpha one antitrypsin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT04385836 Comparator | Jun → Sep 2020 | Coronaviridae infectious disease | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alpha one antitrypsin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04385836 ↗ |
| Known as | alpha1-proteinase inhibitor | “we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days” NCT04385836 ↗ |
| Known as | Glassia | “we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days” NCT04385836 ↗ |